{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17","upperLimit":"51","value":"34"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"Determine the progression-free survival rate among all phase I trial participants who are treated with any of the 4 dose levels of oral clofarabine (1mg, 2mg, 4mg, or 3mg).\n\nProgression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.","dispersionType":"90% Confidence Interval","groups":[{"description":"Clofarabine: Taken orally once a day (in the AM) on days 1 through 21 of a 28-day cycle for a maximum of 6 cycles.","id":"OG000","title":"Phase I"}],"paramType":"MEAN","populationDescription":"Phase I participants only","reportingStatus":"POSTED","timeFrame":"at 17 months","title":"Phase I Participants: Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}